Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01630213 · ClinicalTrials.gov registry record · NA
Impact of Vitamin D Supplementation on Cardiac Structure and Function
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 1,025
- Enrollment target
NCT01630213: Completed NA study, sponsored by Massachusetts General Hospital.
NCT01630213 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 1,025 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (27% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01630213, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,025 participants
- Enrollment target
Study Summary
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in 20,000 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or fish oil (1 gram of omega-3 fatty acids) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study (VITAL-Echo) is being conducted among participants in VITAL and will examine whether vitamin D compared to placebo: (1) reduces left ventricular (LV) mass in elderly individuals as measured with 2-dimensional echocardiography and (2) improves LV systolic and diastolic function as measured with tissue Doppler echocardiography.
Primary Outcome
Primary aim is to examine whether vitamin D supplementation reduces LV mass in elderly individuals, using 2-dimensional echocardiography.
Interventions
- DIETARY_SUPPLEMENT Vitamin D3 + fish oil/fish oil placebo
- DIETARY_SUPPLEMENT Vitamin D3 placebo + fish oil/fish oil placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,025 participants |
| Start Date | 2010-07-01 |
| Est. Completion | 2021-06-30 |
| Phase | NA |
What the finished NCT01630213 record still lists
NCT01630213 is an interventional study that assigns participants to a tested intervention. Its 1,025 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (27% lower).
The record links to 0 conditions, and to 2 interventions - of which Vitamin D3 + fish oil/fish oil placebo is the first listed.
NCT01630213 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01630213 about?
NCT01630213 is a clinical study titled "Impact of Vitamin D Supplementation on Cardiac Structure and Function". The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in 20,000 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or fish oil (1 gram of omega-3 fatty acids) reduces the risk of developing cancer, heart disease, and strok...
What is the current status of trial NCT01630213?
This trial is currently completed. It is a NA study. The enrollment target is 1,025 participants. The study started on 2010-07-01. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT01630213?
The interventions under investigation include: Vitamin D3 + fish oil/fish oil placebo (DIETARY_SUPPLEMENT), Vitamin D3 placebo + fish oil/fish oil placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01630213?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01630213's enrollment target sits among peer trials
1,025 104th of 2000 higher than 1,896 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02200276 · 1,025 participants · NA
Influenza Immunization in Adults Over Age 75
- NCT02296450 · 1,025 participants
Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments
- NCT06888011 · 1,024 participants · NA
iAmHealthy Clinical Practice Guideline (CPG)
- NCT07216703 · 1,023 participants · Phase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI